利奈唑胺通过抑制线粒体翻译预防成纤维细胞活化与组织纤维化
本研究评估利奈唑胺在系统性硬化症(SSc)中的抗纤维化潜力及机制。利奈唑胺抑制TGFβ诱导的成纤维细胞活化,逆转促纤维化基因表达,下调TGFβ、WNT和JAK-STAT信号,减少αSMA表达或应力纤维形成,减少胶原沉积并改善皮肤或肺纤维化。机制上,利奈唑胺抑制成纤维细胞线粒体翻译,阻碍氧化磷酸化,降低NAD+/NADH比值,下调糖酵解。
要点
- 利奈唑胺抑制TGFβ诱导的成纤维细胞活化,减少胶原沉积,改善皮肤或肺纤维化。
- 利奈唑胺下调TGFβ、WNT和JAK-STAT信号,减少αSMA表达或应力纤维形成。
- 机制为抑制线粒体翻译,阻碍氧化磷酸化,降低NAD+/NADH比值,下调糖酵解。
核心结论
- 抑制线粒体翻译的利奈唑胺可改善纤维化组织重塑,首次提供证据。
- 利奈唑胺已作为储备抗生素获批临床,这些发现具有转化前景,支持进一步验证后作为纤维化疾病的新疗法。
研究设计与样本
- 使用人真皮成纤维细胞、人巨噬细胞、三维SSc皮肤等效物(SScSE)、硬化性慢性移植物抗宿主病(sclGvHD)小鼠模型和来自SSc患者的精密切割皮肤切片(PCSS)评估利奈唑胺对纤维化组织重塑的影响。
- 采用RNA测序、免疫荧光、Western blot和组织学;用Seahorse assays和线粒体蛋白合成评估线粒体功能。
主要发现
- 利奈唑胺抑制培养人成纤维细胞、SScSE、sclGvHD小鼠和SSc-PCSS中TGFβ诱导的成纤维细胞活化,表现为逆转促纤维化基因表达程序、下调TGFβ、WNT和JAK-STAT信号、减少αSMA表达或应力纤维形成,导致胶原沉积减少并改善体内皮肤或肺纤维化。
- 机制上,利奈唑胺通过抑制成纤维细胞线粒体翻译诱导代谢改变,阻碍氧化磷酸化,降低NAD+/NADH比值,下调糖酵解(成纤维细胞活化的必需代谢途径)。
临床怎么用
- 利奈唑胺已作为储备抗生素临床获批,这些发现支持进一步验证后作为纤维化疾病的新疗法。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Beyond its role as a ribosome-targeting antibiotic, linezolid was recently shown to modulate immune responses by inhibiting mitochondrial translation. Because mitochondrial dysfunction is implicated in various fibrotic diseases, including systemic sclerosis (SSc), this study aimed to evaluate the antifibrotic potential of linezolid and delineate its underlying mechanisms in SSc. METHODS: The effects of linezolid on fibrotic tissue remodeling were assessed using multiple experimental systems: human dermal fibroblasts, human macrophages, three-dimensional SSc skin equivalents (SScSE), the murine model of sclerodermatous chronic graft-versus-host disease (sclGvHD) and precision-cut skin slices (PCSS) obtained from patients with SSc, RNA sequencing, immunofluorescence, Western blot, and histology. Mitochondrial function was evaluated using Seahorse assays alongside mitochondrial protein synthesis assessments. RESULTS: Linezolid inhibited TGFβ-induced fibroblast activation in cultured human fibroblasts, SScSE, sclGvHD mice, and SSc-PCSS, as demonstrated by reversal of profibrotic gene expression programs, downregulation of TGFβ, WNT, and JAK-STAT signaling, and reductions in αSMA expression or stress fiber formation, which led to reduced collagen deposition and ameliorated skin or lung fibrosis in vivo. Mechanistically, linezolid induced metabolic alterations by inhibiting mitochondrial translation in fibroblasts to hamper the oxidative phosphorylation, reduce the NAD+/NADH ratio, and down-regulate glycolysis, an essential metabolic pathway for fibroblast activation. CONCLUSION: This study provides the first evidence that inhibiting mitochondrial translation with linezolid ameliorates fibrotic tissue remodeling. Because linezolid is already clinically approved as a reserve antibiotic, these findings hold translational promise and support the use of linezolid as a novel treatment for fibrotic disorders after further validation.
引用
- Hong X, Xiao Y, Qi H, et al. Linezolid-mediated Prevention of Fibroblast Activation and Tissue Fibrosis via Mitochondrial Translation Inhibition. Arthritis Rheumatol. 2026. PMID: 41236049. doi:10.1002/art.43440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。